



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava et al.

Confirmation No.:

1802

Serial No.:

09/873,403

Art Unit:

1642

Filed:

June 4, 2001

Examiner:

Christopher H. Yaen

For:

COMPLEXES OF ALPHA (2)

Attorney Docket No:

8449-178-999

MACROGLOBULIN AND ANTIGENIC

Molecules for Immunotherapy

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants respectfully direct the Examiner's attention to the references EM-ER listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references EM-ER are also provided.

Identification of the listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants request that the Examiner review all the references identified on the attached revised PTO Form 1449, and that they be made of record in the file history of the above-identified application. Pursuant to 37 C.F.R. §1.97(a)(4), since this information disclosure statement is being filed concurrently with a Request for Continued Examination under 37 C.F.R. §1.114, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 503013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: April 5, 2004

Adriane M. Antler

By: Cules J. Cules 46,097

Eileen E. Falvey

(Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 790-9090

Sheet 1 of 1

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY DOCKET NO. 8449-178-999		APPLICATION NO 09/873,403	
				APPLICANT Srivastava et al.			
	(APR 0 5 200	x & &)		ing date ine 4, 2001		GROUP 1642	
	CO TOTAL PROPERTY.	U.S. PA	TENT DOCUMEN	ITS			
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME C		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		FOREIGN	PATENT DOCUM	IENTS			

						ATIO
· · · · · · · · · · · · · · · · · · ·	1				YES	N
						\Box
					<u> </u>	<u> </u>
OTHER REFERE	NCES (Inclu	ding Author Title Date 1	Pertinent Pages F	itc)		
	OTHER REFERE	OTHER REFERENCES (Inclu	OTHER REFERENCES (Including Author, Title, Date, 1	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, E	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
EM	Ibe et al., 1998, "Identification and characterization of a cytotoxic T cell epitope of hepatitis
	C virus presented by HLA-B*3501 in acute hepatitis", J. Gen. Virol. 79:1735-1744
EN	Obata et al., 2000, "SEREX analysis of gastric cancer antigens", Cancer Chemother.
	Pharmacol. <u>46(Suppl.):S37-S42</u>
EO	Pfreundschuh, 2000, "Exploitation of the B cell repertoire for the identification of human
	tumor antigens", Cancer Chemother. Pharmacol. 46(Suppl.):S3-S7
EP	Roberts et al., 1996, "Prediction of HIV peptide epitopes by a novel algorithm", AIDS
	Research and Human Retroviruses 12:593-610
EQ	Sette et al., 1989, "Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis", Proc. Natl. Acad. Sci. USA <u>86</u> :3296-3300
ER	ePitope Informatics - prediction and analysis of protein epitopes - references [online] [retrieved 3/15/2004] <urrl: http:="" references="" www.epitope-informatics.com=""></urrl:>

EXAMINER	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				